Production of heterodimeric proteins

Patent metadata

Field	Value
Publication number	US-10344050-B2
Application number	US-201214353962-A
Country	US
Kind code	B2
Filing date	Oct 26, 2012
Priority date	Oct 27, 2011
Publication date	Jul 9, 2019
Grant date	Jul 9, 2019

Abstract

The present invention relates to an in vitro method for production of heterodimeric proteins.

First claim

The invention claimed is:

1. An in vitro method for production of a heterodimeric antibody comprising the following steps:
a) incubating a first chimeric, humanized, or human homodimeric antibody with a second chimeric, humanized, or human homodimeric antibody under reducing conditions sufficient to allow reduction of the inter-chain disulfide bonds in the hinge region, and wherein said first homodimeric antibody comprises an Fc region of an immunoglobulin, said Fc region comprising a first human IgG4 CH3 region, and said second homodimeric antibody comprises an Fc region of an immunoglobulin, said Fc region comprising a second human IgG4 CH3 region, wherein said first homodimeric antibody has an Arg at position 409 (numbering according to the EU Index), and said second homodimeric antibody has an amino acid substitution selected from the group consisting of: L368A, L368D, L368E, L368G, L368H, L368I, L368N, L368Q, L368R, L368S, L368T, L368V, L368W, D399A, D399F, D399H, D399K, D399R, D399Y, F405A, F405D, F405E, F405H, F4051, F405K, F405L, F405M, F405N, F405Q, F405S, F405T, F405V, F405W, F405Y, Y407G, Y407L, Y407M, and Y407W (numbering according to the EU Index), wherein the sequences of said first and second CH3 regions are different and are such that the heterodimeric interaction between said first and second CH3 regions is stronger than each of the homodimeric interactions of said first and second CH3 regions, and wherein the reducing conditions comprise adding a reducing agent,
b) subjecting the composition obtained from step a) to oxidizing conditions sufficient to allow oxidation of cysteines in the heterodimeric antibody to inter-chain disulfide bonds, and
c) obtaining the heterodimeric antibody.

2. The method according to claim 1 , wherein step b) comprises subjecting at least 10 mL of the composition obtained from step a) to oxidizing conditions sufficient to allow oxidation.

3. The method according to claim 1 , wherein the reducing agent is selected from the group consisting of: 2-mercaptoethylamine, a chemical derivative of 2-mercaptoethylamine, L-cysteine, and D-cysteine.

4. The method according to claim 1 , wherein step a) comprises adding a metal chelating agent.

5. The method according to claim 4 , wherein the metal chelating agent is EDTA, EGTA, or citric acid.

6. The method according to claim 1 , wherein the reducing conditions in step a) comprise reducing the amount of oxygen in the composition in step a).

7. The method according to claim 1 , wherein step a) is performed under reducing conditions with a redox potential between −150 and −600 mV.

8. The method according to claim 1 , wherein step a) comprises incubation for at least 30 min at a temperature of at least 20° C. in the presence of at least 25 mM of a reducing agent selected from the group consisting of 2-mercaptoethylamine, L-cysteine, and D-cysteine.

9. The method according to claim 1 , wherein the first and second homodimeric antibodies are in a buffer.

10. The method according to claim 9 , wherein the buffer comprises in the range of 1-100 mM phosphate.

11. The method according to claim 9 , wherein the buffer has a pH in the range of 4.5-8.5.

12. The method according to claim 9 , wherein the buffer is selected from the group consisting of a) 8.1 mM sodium phosphate (Na 2 HPO 4 -7H 2 O), 1.5 mM potassium phosphate (KH 2 PO 4 ), 138 mM sodium chloride (NaCl), 2.7 mM potassium chloride (KCl) pH 5.0; b) 8.1 mM sodium phosphate (Na 2 HPO 4 -7H 2 O), 1.5 mM potassium phosphate (KH 2 PO 4 ), 138 mM sodium chloride (NaCl), 2.7 mM potassium chloride (KCl) pH 7.0; and c) 20 mM Tris-HCl, pH 7.8.

13. The method according to claim 1 , wherein step b) comprises a pH in the range of 6-8.5.

14. The method according to claim 1 , wherein step b) comprises a redox potential of at least −300 mV.

15. The method according to claim 1 , wherein the oxidizing conditions in step b) comprise the presence of at least 0.05 mM oxygen.

16. The method according to claim 1 , wherein the oxidizing conditions in step b) comprise adding oxygen.

17. The method according to claim 16 , wherein adding oxygen is performed mechanically.

18. The method according to claim 16 , wherein adding oxygen is performed by sparging with oxygen or air or increasing pressure.

19. The method according to claim 1 , wherein the oxidizing conditions in step b) comprise an oxidizing agent.

20. The method according to claim 19 , wherein the oxidizing agent is dehydroascorbic acid (dhAA).

21. The method according to claim 1 , wherein step b) comprises separating the heterodimeric antibody and the reducing agent.

22. The method according to claim 21 , wherein step b) comprises subjecting the composition obtained from step a) to chromatography or filtration.

23. The method according to claim 22 , wherein the chromatography is column chromatography.

24. The method according to claim 22 , wherein the filtration is diafiltration.

25. A method according to claim 24 , wherein the diafiltration is tangential flow filtration (TFF) or normal flow filtration (NFF).

26. The method according to claim 25 , wherein the diafiltration is TFF.

27. The method according to claim 25 , wherein the diafiltration is performed by circulating the composition through a hollow fiber cartridge comprising a cut-off value in the range of 10-50 kDa, and with a surface area in the range of 0.05-1 m 2 , and with a cartridge inlet pressure in the range of 70-280 kPa, until one to seven volumes of buffer exchange have taken place.

28. The method according to claim 21 , wherein separating the heterodimeric antibody and the reducing agent comprises exchanging the buffer or solution of the composition obtained from step a) with a buffer or solution without said reducing agent.

29. The method according to claim 28 , comprising in the range of 3-12 volumes of buffer or solution exchanges.

30. The method according to claim 22 , wherein separating the heterodimeric antibody and the reducing agent is a continuous process.

31. The method according to claim 22 , wherein separating the heterodimeric antibody and the reducing agent is a batch process.

32. The method according to claim 1 , wherein the oxidizing conditions in step b) comprise the steps of:
I) diafiltration of the composition obtained from step a);
II) incubation of the retentate obtained from step I); and
III) diafiltration of the composition obtained from step II).

33. The method according to claim 32 , wherein the diafiltration in steps I) and/or III) comprises in the range of 3-12 volumes of buffer exchange.

34. The method according to claim 32 , wherein step II) comprises incubation at a temperature in the range of 15-35° C. for a period of 12-48 hours.

35. The method according to claim 1 , wherein the concentration of heterodimeric antibody in the composition obtained from step a) is in the range of 1-100 g/L.

36. The method according to claim 1 , wherein the oxidizing conditions in step b) comprise a metal ion.

37. The method according to claim 36 , wherein the oxidizing conditions in step b) comprise adding a metal ion.

38. The method according to claim 36 , wherein the concentration of the metal ion is in the range

Assignees

• Genmab As

Inventors

• Gramer Michael
• Kundu Amitava
• Van Den Bremer Ewald T J
• Van Kampen Muriel
• Priem Patrick
• Labrijn Aran Frank
• Meesters Joyce I
• Neijssen Joost J
• Schuurman Janine
• Parren Paul
• Van Berkel Patrick
• Vos Werner L
• Gerritsen Arnout

Classifications

• C07K2317/526

  CH3 domain · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K16/2887

  against CD20 · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title